The global genitourinary drugs market is accounted for USD 28,200 million expected and expected to register CAGR ~1.65% during the forecast period (2018–2023).
Genitourinary disorders are caused by damage to urinal or genital part of the human body. Kidney, bladder, ureter and urethra are parts of genitourinary system, genitourinary drugs are used to treat the medical complications caused to these parts. The rising prevalence of genitourinary disorders, increasing number of pipeline drugs, and technological advancement in genitourinary diagnosis are expected to drive the growth of the market. According to the U.S. National Library of Medicine more than 480 clinical trials are lined up for treatment of urinary tract infection.
Health Information Center, Moreover, rising R&D spending and collaborative strategies adopted by the top players such as licensing and agreements are contributing to the growth of the market. For instance, in October 2018, Novartis AG signed a licensing agreement with Boston Pharmaceuticals for manufacturing and marketing of its three anti-infective products LYS228, IID572, and MAK181.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6802
The increasing emergence of counterfeit drugs, rising generics drug competition, and high number of patent expirations may hamper the growth of the market during the assessment period.
Regional Analysis
The market in the Americas is expected to dominate the global genitourinary drugs market during the forecast period owing to the rising prevalence of genitourinary disorders, increasing cancer patients in the region, rise in healthcare expenditure, and the presence of a well-established healthcare system. The European market is expected to be the second-largest due to the government initiatives for the development of healthcare sector, increasing research and development activities in the region and rise in number of chronic disorders. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the increasing geriatric population, rising investments in healthcare sector and favorable government policies. The market in the Middle East & Africa is likely to account for the smallest genitourinary drugs market share. The market growth in this region can be attributed to increasing healthcare expenditure and growing medical tourism.
Segmentation
The global genitourinary drugs market has been segmented on the basis of disease, product, and end-user.
The market, by disease, has been classified as urinary tract infections, erectile dysfunction, urinary incontinence & overactive bladder, kidney/renal cancer, genitourinary cancer, bladder cancer, bladder cancer, cervical cancer, sexually transmitted diseases, interstitial cystitis, hematuria, ovarian cancer, and prostate cancer.
On the basis of product, the market has been segregated into urologicals, hormonal therapy, gynecologicals, and anti-infectives.
The end-user segment has been divided into, hospitals, clinics, super specialty centers, and others.
Key Players
Some of the key players in the global genitourinary drugsmarket are Bayer AG,AstraZeneca ,Abbott,Astellas Pharma Inc.,Pfizer Inc.,Eli Lilly and Company,Genentech, Inc.,Immunex Corp. GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc.,Merck & Co.,Bristol-Myers Squibb Company,Antares Pharma,and Novartis AG
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/genitourinary-drugs-market-6802
No comments:
Post a Comment